Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases

Detalles Bibliográficos
Autores principales: Andreev-Drakhlin, Alexander, Cabanillas, Maria, Amini, Behrang, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608524/
https://www.ncbi.nlm.nih.gov/pubmed/33154983
http://dx.doi.org/10.1200/PO.20.00096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608524/
https://www.ncbi.nlm.nih.gov/pubmed/33154983
http://dx.doi.org/10.1200/PO.20.00096

Ejemplares similares